Insuman Infusat

Insulin Human, the active ingredient in Insuman Infusat, is an insulin presented as a sterile solution for subcutaneous use. It lowers blood glucose levels and is used in the management of diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Insuman Infusat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. The company adheres to stringent quality standards and provides reliable logistics for timely delivery.

Insuman Infusat (insulin human) is used in the insulin pathway to control hyperglycemia in diabetes mellitus. - Type 1 diabetes mellitus: provides basal and prandial insulin to achieve glycemic control. - Type 2 diabetes mellitus: supplements endogenous insulin to improve blood glucose regulation. - Diabetic ketoacidosis: used as part of emergency insulin therapy to reduce plasma glucose levels.

Common Side Effects: - Hypoglycemia (low blood sugar). - Injection‑site pain, redness or swelling. - Weight gain. - Lipodystrophy at injection sites. - Peripheral edema.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Hypokalemia. - Acute insulin overdose leading to seizures or coma. - Stevens‑Johnson syndrome (very rare).

Before using Insuman Infusat, consider the following precautions: - Dose titration: adjust based on self‑monitoring of blood glucose. - Hypoglycemia risk: educate patients on recognizing and treating low glucose episodes. - Renal impairment: may require lower doses and close monitoring. - Hepatic impairment: monitor glucose closely and adjust therapy as needed. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Infusat may interact with other medicines as follows:

Major Interactions (Avoid): - Concurrent use of other insulin products: risk of severe hypoglycemia. - Beta‑adrenergic blockers: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Sulfonylureas or meglitinides: additive glucose‑lowering effect; monitor for hypoglycemia. - ACE inhibitors or ARBs: may enhance insulin sensitivity; monitor glucose levels. - Thiazide diuretics: may increase blood glucose; adjust therapy as needed. - Oral corticosteroids: may raise glucose; consider dose adjustments.